#read
Back to news overview

BioMed X and Daiichi Sankyo join forces for new cancer research in Heidelberg

The BioMed X Institute in Heidelberg is launching a new research project that has the potential to fundamentally change cancer therapy. A team led by Dr Reda Benmebarek, together with the Japanese pharmaceutical company Daiichi Sankyo, is researching novel multispecific biologics that simultaneously address several targets in the tumour microenvironment.
23/10/2025

These biologics are designed to specifically recruit immune cells and activate strong defence reactions against solid tumours. They could thus overcome the limitations of conventional therapies and pave the way for new treatment strategies. Dr Benmebarek brings with him experience from the National Institutes of Health in the USA and LMU Munich. The BioMed X Institute is recognised as one of the most innovative research hubs in Europe and links cutting-edge academic research with industrial development. The new project strengthens Heidelberg's position as a global centre for translational cancer research and biotech innovation.

Press release from "BioMed X" dated 23 October 2025

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content